ArticleCureus2024
Outcome, Complications, and Survival of Sarcomas of the Extremities Treated With Mega Prostheses: A Comprehensive Analysis of 115 Cases in a Cancer-Dedicated Hospital.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The first limb-sparing use of histotripsy for canine osteosarcoma.Scientific reports · 2026Article
- AnOncology research · 2026Article
- Management of periprosthetic proximal femoral fracture of megaprosthesis with limited residual bone stock: A case report.International journal of surgery case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn the late 20th century, limb salvage surgery emerged as a game-changer for treating musculoskeletal tumors, evolving with advanced techniques to offer both survival and functional preservation. The objective of the study is to discuss key metrics, such as overall survival, metastasis-free survival, local recurrence-free survival, and functional outcomes, recognizing the importance of these measures. Despite hurdles such as potential infections and implant issues, it is crucial to understand and address complications, which is also highlighted in this study.
methodsThis was a retrospective review of patients with primary malignant bone tumors from January 2017 to December 2023 and the progress was followed up till June 2024. Variables assessed included patient age, size and anatomical location of the primary tumor, metastasis, histological subtype, stage and grade of tumor, resection margins, treatment provided, functional outcome, and complications. The data were analyzed with SPSS version 27. Five-year metastasis-free survival, recurrence-free survival, and overall survival were analyzed by using the Kaplan-Meier method.
resultsA total of 115 patients were analyzed, among which the most common type of tumor was osteosarcoma, found in 79 (68.7%) patients. Out of the 115 patients, 20 (17.4%) expired, six were lost to follow-up, and the five-year overall survival rate was approximately 78% (95% CI: 69.6-87.5%). Fourteen (12.2%) patients had local recurrence, and the five-year recurrence-free survival rate was approximately 83.2% (95% CI: 74.4-92.6%). Meanwhile, 27 (23.5%) patients had distant metastasis, and the five-year metastasis-free survival rate was approximately 67.5% (95% CI: 55.3-82.3%). Complications occurred in 31 (27%) patients, with 13 (11.3%) patients having local soft-tissue-related complications.
conclusionWe observed good survival and functional outcomes in patients treated with wide-margin excision of bone sarcomas and reconstruction with mega prostheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.